The role of cyclooxygenases and lipoxygenases in the regulation of tumor angiogenesis

Tumor Angiogenesis Regulators

Volumn , Issue , 2013, Pages 239-296

  Pidgeon, Graham ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Angiogenesis; Cancer; Cyclooxygenase; Lipoxygenase; Metastasis; Natural agents; Pharmacological inhibitors; Prostaglandins; Thromboxane synthase

Indexed keywords

EID: 84977740369     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14842     Document Type: Chapter

References (302)

1. Abdel-Majid, R. M. and J. S. Marshall (2004). “Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells.” J Immunol 172(2): 1227-1236.
2. Achiwa, H., Y. Yatabe, T. Hida, T. Kuroishi, K. Kozaki, S. Nakamura, M. Ogawa, T. Sugiura, T. Mitsudomi and T. Takahashi (1999). “Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.” Clin Cancer Res 5(5): 1001-1005.
3. Aggarwal, B. B., A. Bhardwaj, R. S. Aggarwal, N. P. Seeram, S. Shishodia and Y. Takada (2004). “Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.” Anticancer Res 24(5A): 2783-2840.
4. Alfranca, A., M. A. Iniguez, M. Fresno and J. M. Redondo (2006). “Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases.” Cardiovasc Res 70(3): 446-456.
5. Amano, H., I. Hayashi, H. Endo, H. Kitasato, S. Yamashina, T. Maruyama, M. Kobayashi, K. Satoh, M. Narita, Y. Sugimoto, T. Murata, H. Yoshimura, S. Narumiya and M. Majima (2003). “Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth.” J Exp Med 197(2): 221-232.
6. Amatruda, J. F., J. L. Shepard, H. M. Stern and L. I. Zon (2002). “Zebrafish as a cancer model system.” Cancer Cell 1(3): 229-231.
7. Antonarakis, E. S., E. I. Heath, J. R. Walczak, W. G. Nelson, H. Fedor, A. M. De Marzo, M. L. Zahurak, S. Piantadosi, A. J. Dannenberg, R. T. Gurganus, S. D. Baker, H. L. Parnes, T. L. DeWeese, A. W. Partin and M. A. Carducci (2009). “Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.” J Clin Oncol 27(30): 4986-4993.
8. Arisato, T., T. Hashiguchi, K. P. Sarker, K. Arimura, M. Asano, K. Matsuo, M. Osame and I. Maruyama (2003). “Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region.” J Thromb Haemost 1(12): 2589-2593.
9. Asano, K., H. Nakamura, C. M. Lilly, M. Klagsbrun and J. M. Drazen (1997). “Interferon gamma induces prostaglandin G/H synthase-2 through an autocrine loop via the epidermal growth factor receptor in human bronchial epithelial cells.” J Clin Invest 99(5): 1057-1063.
10. 2receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alpha(v)beta3.” Circ Res 94(6): 735-742.
11. 2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration.” Circ Res 95(4): 372-379.
12. Ashton, A. W., R. Yokota, G. John, S. Zhao, S. O. Suadicani, D. C. Spray and J. A. Ware (1999). “Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2).” J Biol Chem 274(50): 35562-35570.
13. Barry, M., R. A. Cahill, G. Roche-Nagle, T. G. Neilan, A. Treumann, J. H. Harmey and D. J. Bouchier-Hayes (2009). “Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer.” Ir J Med Sci 178(2): 201-208.
14. Bhowmick, N. A., E. G. Neilson and H. L. Moses (2004). “Stromal fibroblasts in cancer initiation and progression.” Nature 432(7015): 332-337.
15. Binion, D. G., M. F. Otterson and P. Rafiee (2008). “Curcumin inhibits VEGFmediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition.” Gut 57(11): 1509-1517.
16. Biscetti, F., E. Gaetani, A. Flex, G. Straface, G. Pecorini, F. Angelini, E. Stigliano, T. Aprahamian, R. C. Smith, J. J. Castellot and R. Pola (2009). “Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation.” J Vasc Res 46(2): 103-108.
17. Bishop-Bailey, D. (2000). “Peroxisome proliferator-activated receptors in the cardiovascular system.” Br J Pharmacol 129(5): 823-834.
18. Bogatcheva, N. V., M. G. Sergeeva, S. M. Dudek and A. D. Verin (2005). “Arachidonic acid cascade in endothelial pathobiology.” Microvasc Res 69(3): 107-127.
19. Bombardier, C., L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M. B. Ferraz, C. J. Hawkey, M. C. Hochberg, T. K. Kvien and T. J. Schnitzer (2000). “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.” N Engl J Med 343(21): 1520-1528, 1522 p following 1528.
20. Brabender, J., J. Park, R. Metzger, P. M. Schneider, R. V. Lord, A. H. Holscher, K. D. Danenberg and P. V. Danenberg (2002). “Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer.” Ann Surg 235(3): 440-443.
21. Brash, A. R., W. E. Boeglin and M. S. Chang (1997). “Discovery of a second 15S-lipoxygenase in humans.” Proc Natl Acad Sci USA 94(12): 6148-6152.
22. Bresalier, R. S., R. S. Sandler, H. Quan, J. A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, M. A. Konstam and J. A. Baron (2005). “Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.” N Engl J Med 352(11): 1092-1102.
23. Buchanan, F. G., W. Chang, H. Sheng, J. Shao, J. D. Morrow and R. N. DuBois (2004). “Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor.” Gastroenterology 127(5): 1391-1400.
24. Buchanan, F. G., D. L. Gorden, P. Matta, Q. Shi, L. M. Matrisian and R. N. DuBois (2006). “Role of beta-arrestin 1 in the metastatic progression of colorectal cancer.” Proc Natl Acad Sci USA 103(5): 1492-1497.
25. Buchanan, F. G., D. Wang, F. Bargiacchi and R. N. DuBois (2003). “Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor.” J Biol Chem 278(37): 35451-35457.
26. Casanovas, O., D. J. Hicklin, G. Bergers and D. Hanahan (2005). “Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.” Cancer Cell 8(4): 299-309.
27. Catalano, A. and A. Procopio (2005). “New aspects on the role of lipoxygenases in cancer progression.” Histol Histopathol 20(3): 969-975.
28. Cathcart, M. C., K. Gately, R. Cummins, E. Kay, O. B. KJ and G. P. Pidgeon (2011). “Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.” Mol Cancer 10(1): 25.
29. Cathcart, M. C., J. Lysaght and G. P. Pidgeon (2011). “Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention.” Cancer Metastasis Rev 30(3-4): 363-385.
30. Cathcart, M. C., R. Tamosiuniene, G. Chen, T. G. Neilan, A. Bradford, K. J. O’Byrne, D. J. Fitzgerald and G. P. Pidgeon (2008). “Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis.” J Pharmacol Exp Ther 326(1): 51-58.
31. Celotti, F. and T. Durand (2003). “The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.” Prostaglandins Other Lipid Mediat 71(3-4): 147-162.
32. Cespedes, M. V., I. Casanova, M. Parreno and R. Mangues (2006). “Mouse models in oncogenesis and cancer therapy.” Clin Transl Oncol 8(5): 318-329.
33. Chang, S. H., C. H. Liu, R. Conway, D. K. Han, K. Nithipatikom, O. C. Trifan, T. F. Lane and T. Hla (2004). “Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression.” Proc Natl Acad Sci USA 101(2): 591-596.
34. Chatterjee, M., S. Das and K. Roy (2011). “Overexpression of 5-lipoxygenase and its relation with cell proliferation and angiogenesis in 7,12-dimethylbenz(alpha) anthracene-induced rat mammary carcinogenesis.” Mol Carcinog Dec. 28 [Epub ahead of print].
35. Chen, X., S. Wang, N. Wu, S. Sood, P. Wang, Z. Jin, D. G. Beer, T. J. Giordano, Y. Lin, W. C. Shih, R. A. Lubet and C. S. Yang (2004). “Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.” Clin Cancer Res 10(19): 6703-6709.
36. Cheng, T., W. Cao, R. Wen, R. H. Steinberg and M. M. LaVail (1998). “Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells.” Invest Ophthalmol Vis Sci 39(3): 581-591.
37. Chiu, Y. W., T. H. Lin, W. S. Huang, C. Y. Teng, Y. S. Liou, W. H. Kuo, W. L. Lin, H. I. Huang, J. N. Tung, C. Y. Huang, J. Y. Liu, W. H. Wang, J. M. Hwang and H. C. Kuo (2011). “Baicalein inhibits the migration and invasive properties of human hepatoma cells.” Toxicol Appl Pharmacol 255(3): 316-326.
38. Cianchi, F., C. Cortesini, P. Bechi, O. Fantappie, L. Messerini, A. Vannacci, I. Sardi, G. Baroni, V. Boddi, R. Mazzanti and E. Masini (2001). “Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.” Gastroenterology 121(6): 1339-1347.
39. Conrad, D. J. (1999). “The arachidonate 12/15 lipoxygenases. A review of tissue expression and biologic function.” Clin Rev Allergy Immunol 17(1-2): 71-89.
40. Cuendet, M. and J. M. Pezzuto (2000). “The role of cyclooxygenase and lipoxygenase in cancer chemoprevention.” Drug Metabol Drug Interact 17(1-4): 109-157.
41. Cuneo, K. C., A. Fu, K. L. Osusky and L. Geng (2007). “Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis.” Anticancer Drugs 18(3): 349-355.
42. D’Amato, R. J., M. S. Loughnan, E. Flynn and J. Folkman (1994). “Thalidomide is an inhibitor of angiogenesis.” Proc Natl Acad Sci USA 91(9): 4082-4085.
43. Daneker, G. W., S. A. Lund, S. W. Caughman, C. A. Staley and W. C. Wood (1996). “Anti-metastatic prostacyclins inhibit the adhesion of colon carcinoma to endothelial cells by blocking E-selectin expression.” Clin Exp Metastasis 14(3): 230-238.
44. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.” Cancer Res 59(18): 4574-4577.
45. 2modulators as antiangiogenic agents.” J Pharmacol Exp Ther 318(3): 1057-1067.
46. 2 synthesis in Caco-2 human colon carcinoma cells.” Oncogene 19(48): 5517-5524.
47. Dicker, A. P., T. L. Williams and D. S. Grant (2001). “Targeting angiogenic processes by combination rofecoxib and ionizing radiation.” Am J Clin Oncol 24(5): 438-442.
48. 2 up-regulates vascular endothelial growth factor expression in MKN28 gastric cancer cells via epidermal growth factor receptor signaling system.” Exp Oncol 27(2): 108-113.
49. Dirig, D. M., P. C. Isakson and T. L. Yaksh (1998). “Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats.” J Pharmacol Exp Ther 285(3): 1031-1038.
50. Dominguez-Jimenez, C., F. Diaz-Gonzalez, I. Gonzalez-Alvaro, J. M. Cesar and F. Sanchez-Madrid (1999). “Prevention of alphaII(b)beta3 activation by nonsteroidal antiinflammatory drugs.” FEBS Lett 446(2-3): 318-322.
51. Dormond, O., M. Bezzi, A. Mariotti and C. Ruegg (2002). “Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, racactivation, and spreading through cAMP/PKA-dependent signaling.” J Biol Chem 277(48): 45838-45846.
52. Dormond, O., A. Foletti, C. Paroz and C. Ruegg (2001). “NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.” Nat Med 7(9): 1041-1047.
53. Dragovich, T., H. Burris, 3rd, P. Loehrer, D. D. Von Hoff, S. Chow, S. Stratton, S. Green, Y. Obregon, I. Alvarez and M. Gordon (2008). “Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.” Am J Clin Oncol 31(2): 157-162.
54. Edelman, M. J., L. Hodgson, X. Wang, R. Christenson, S. Jewell, E. Vokes and R. Kratzke (2011). “Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.” J Thorac Oncol 6(11): 1902-1906.
55. Edelman, M. J., D. Watson, X. Wang, C. Morrison, R. A. Kratzke, S. Jewell, L. Hodgson, A. M. Mauer, A. Gajra, G. A. Masters, M. Bedor, E. E. Vokes and M. J. Green (2008). “Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B Trial 30203.” J Clin Oncol 26(6): 848-855.
56. Ermert, L., C. Dierkes and M. Ermert (2003). “Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors.” Clin Cancer Res 9(5): 1604-1610.
57. Fabre, J. E., J. L. Goulet, E. Riche, M. Nguyen, K. Coggins, S. Offenbacher and B. H. Koller (2002). “Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo.” J Clin Invest 109(10): 1373-1380.
58. Faronato, M., G. Muzzonigro, G. Milanese, C. Menna, A. R. Bonfigli, A. Catalano and A. Procopio (2007). “Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma.” Histol Histopathol 22(10): 1109-1118.
59. Fegn, L. and Z. Wang (2009). “Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.” J Laryngol Otol 123(8): 880-884.
60. Fenwick, S. W., G. J. Toogood, J. P. Lodge and M. A. Hull (2003). “The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.” Gastroenterology 125(3): 716-729.
61. Fidler, I. J. and L. M. Ellis (1994). “The implications of angiogenesis for the biology and therapy of cancer metastasis.” Cell 79(2): 185-188.
62. Fidler, M. J., A. Argiris, J. D. Patel, D. H. Johnson, A. Sandler, V. M. Villaflor, J. T. Coon, L. Buckingham, K. Kaiser, S. Basu and P. Bonomi (2008). “The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.” Clin Cancer Res 14(7): 2088-2094.
63. Finetti, F., S. Donnini, A. Giachetti, L. Morbidelli and M. Ziche (2009). “Prostaglandin E(2) primes the angiogenic switch via a synergic interaction with the fibroblast growth factor-2 pathway.” Circ Res 105(7): 657-666.
64. Finetti, F., R. Solito, L. Morbidelli, A. Giachetti, M. Ziche and S. Donnini (2008). “Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1.” J Biol Chem 283(4): 2139-2146.
65. Fiorucci, S., E. Distrutti, A. Mencarelli, A. Morelli, S. A. Laufor, G. Cirino and J. L. Wallace (2003). “Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin.” Br J Pharmacol 139(7): 1351-1359.
66. Fu, Y. G., J. J. Sung, K. C. Wu, A. H. Bai, M. C. Chan, J. Yu, D. M. Fan and W. K. Leung (2006). “Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin J2 through the downregulation of angiopoietin-1.” Cancer Lett 243(2): 246-254.
67. Fujino, H., K. Toyomura, X. B. Chen, J. W. Regan and T. Murayama (2011). “Prostaglandin E regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells.” Biochem Pharmacol 81(3): 379-387.
68. Fujita, J., J. R. Mestre, J. B. Zeldis, K. Subbaramaiah and A. J. Dannenberg (2001). “Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2.” Clin Cancer Res 7(11): 3349-3355.
69. Fukuda, R., B. Kelly and G. L. Semenza (2003). “Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1.” Cancer Res 63(9): 2330-2334.
70. Funk, C. D. (1993). “Molecular biology in the eicosanoid field.” Prog Nucleic Acid Res Mol Biol 45: 67-98.
71. Funk, C. D. (2001). “Prostaglandins and leukotrienes: advances in eicosanoid biology.” Science 294(5548): 1871-1875.
72. Funk, C. D. and G. A. FitzGerald (2007). “COX-2 inhibitors and cardiovascular risk.” J Cardiovasc Pharmacol 50(5): 470-479.
73. Funovics, P., C. Brostjan, A. Nigisch, A. Fila, A. Grochot, K. Mleczko, H. Was, G. Weigel, J. Dulak and A. Jozkowicz (2006). “Effects of 15d-PGJ(2) on VEGFinduced angiogenic activities and expression of VEGF receptors in endothelial cells.” Prostaglandins Other Lipid Mediat 79(3-4): 230-244.
74. Furstenberger, G., P. Krieg, K. Muller-Decker and A. J. Habenicht (2006). “What are cyclooxygenases and lipoxygenases doing in the driver’s seat of carcinogenesis?" Int J Cancer 119(10): 2247-2254.
75. 2 receptor activation in rats.” Am J Physiol 273(2 Pt 2): H734-739.
76. Gao, X., D. J. Grignon, T. Chbihi, A. Zacharek, Y. Q. Chen, W. Sakr, A. T. Porter, J. D. Crissman, J. E. Pontes, I. J. Powell and et al. (1995). “Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer.” Urology 46(2): 227-237.
77. Gao, Y., R. Yokota, S. Tang, A. W. Ashton and J. A. Ware (2000). “Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thromboxane A(2).” Circ Res 87(9): 739-745.
78. Gerhardt, H. and C. Betsholtz (2003). “Endothelial-pericyte interactions in angiogenesis.” Cell Tissue Res 314(1): 15-23.
79. Giese, A., C. Hagel, E. L. Kim, S. Zapf, J. Djawaheri, M. E. Berens and M. Westphal (1999). “Thromboxane synthase regulates the migratory phenotype of human glioma cells.” Neuro Oncol 1(1): 3-13.
80. Giese, A., M. A. Loo, M. D. Rief, N. Tran and M. E. Berens (1995). “Substrates for astrocytoma invasion.” Neurosurgery 37(2): 294-301; discussion 301-292.
81. Gilroy, D. W., A. Tomlinson and D. A. Willoughby (1998). “Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation.” Eur J Pharmacol 355(2-3): 211-217.
82. Gonzalez, A. L., R. L. Roberts, P. P. Massion, S. J. Olson, Y. Shyr and S. B. Shappell (2004). "15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation.” Hum Pathol 35(7): 840-849.
83. Grau, R., M. A. Iniguez and M. Fresno (2004). “Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.” Cancer Res 64(15): 5162-5171.
84. Greene, E. R., S. Huang, C. N. Serhan and D. Panigrahy (2011). “Regulation of inflammation in cancer by eicosanoids.” Prostaglandins Other Lipid Mediat: Epub.
85. Griesser, M., T. Suzuki, N. Tejera, S. Mont, W. E. Boeglin, A. Pozzi and C. Schneider (2011). “Biosynthesis of hemiketal eicosanoids by cross-over of the 5-lipoxygenase and cyclooxygenase-2 pathways.” Proc Natl Acad Sci USA 108(17): 6945-6950.
86. Griffioen, A. W. and G. Molema (2000). “Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.” Pharmacol Rev 52(2): 237-268.
87. Guo, Y., W. Zhang, C. Giroux, Y. Cai, P. Ekambaram, A. K. Dilly, A. Hsu, S. Zhou, K. R. Maddipati, J. Liu, S. Joshi, S. C. Tucker, M. J. Lee and K. V. Honn (2011). “Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid.” J Biol Chem 286(39): 33832-33840.
88. Gupta, R. A., T. J., W. F. Krause, M. Geraci, T. M. Willson and S. K. Dey (2000). “Prostacyclin mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.” Proc Natl Acad Sci USA 97: 13275-13280.
89. Gupta, S., M. Srivastava, N. Ahmad, K. Sakamoto, D. G. Bostwick and H. Mukhtar (2001). “Lipoxygenase-5 is overexpressed in prostate adenocarcinoma.” Cancer 91(4): 737-743.
90. Gyftopoulos, K., K. Vourda, G. Sakellaropoulos, P. Perimenis, A. Athanasopoulos and E. Papadaki (2011). “The Angiogenic Switch for Vascular Endothelial Growth Factor-A and Cyclooxygenase-2 in Prostate Carcinoma: Correlation with Microvessel Density, Androgen Receptor Content and Gleson Grade.” Urol Int 87(4): 464-9.
91. Hanahan, D. and J. Folkman (1996). “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.” Cell 86(3): 353-364.
92. Hanahan, D. and R. A. Weinberg (2011). “Hallmarks of cancer: the next generation.” Cell 144(5): 646-674.
93. Harris, R. C., J. A. McKanna, Y. Akai, H. R. Jacobson, R. N. Dubois and M. D. Breyer (1994). “Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction.” J Clin Invest 94(6): 2504-2510.
94. Haslmayer, P., T. Thalhammer, W. Jager, S. Aust, G. Steiner, C. Ensinger and P. Obrist (2002). “The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637.” Int J Oncol 21(4): 915-920.
95. Hata, A. N. and R. M. Breyer (2004). “Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation.” Pharmacol Ther 103(2): 147-166.
96. Hazai, E., Z. Bikadi, F. Zsila and S. F. Lockwood (2006). “Molecular modeling of the non-covalent binding of the dietary tomato carotenoids lycopene and lycophyll, and selected oxidative metabolites with 5-lipoxygenase.” Bioorg Med Chem 14(20): 6859-6867.
97. He, T., T. Lu, L. V. d’Uscio, C. F. Lam, H. C. Lee and Z. S. Katusic (2008). “Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells.” Circ Res 103(1): 80-88.
98. Heath, E. I., M. I. Canto, S. Piantadosi, E. Montgomery, W. M. Weinstein, J. G. Herman, A. J. Dannenberg, V. W. Yang, A. O. Shar, E. Hawk and A. A. Forastiere (2007). “Secondary chemoprevention of Barrett’s esophagus with celecoxib: results of a randomized trial.” J Natl Cancer Inst 99(7): 545-557.
99. Herbst, R. S., A. Onn and A. Sandler (2005). “Angiogenesis and lung cancer: prognostic and therapeutic implications.” J Clin Oncol 23(14): 3243-3256.
100. Hernandez, G. L., O. V. Volpert, M. A. Iniguez, E. Lorenzo, S. Martinez-Martinez, R. Grau, M. Fresno and J. M. Redondo (2001). “Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.” J Exp Med 193(5): 607-620.
101. Hla, T. and K. Neilson (1992). “Human cyclooxygenase-2 cDNA.” Proc Natl Acad Sci USA 89(16): 7384-7388.
102. Ho, T. C., S. L. Chen, Y. C. Yang, C. Y. Chen, F. P. Feng, J. W. Hsieh, H. C. Cheng and Y. P. Tsao (2008). "15-deoxy-Delta(12,14)-prostaglandin J2 induces vascular endothelial cell apoptosis through the sequential activation of MAPKS and p53.” J Biol Chem 283(44): 30273-30288.
103. Hoffmann, C. (2000). “COX-2 in brain and spinal cord implications for therapeutic use.” Curr Med Chem 7(11): 1113-1120.
104. Hong, J., M. Bose, J. Ju, J. H. Ryu, X. Chen, S. Sang, M. J. Lee and C. S. Yang (2004). “Modulation of arachidonic acid metabolism by curcumin and related betadiketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase.” Carcinogenesis 25(9): 1671-1679.
105. 2 system.” Clin Exp Metastasis 1(2): 103-114.
106. Honn, K. V., B. Cicone and A. Skoff (1981). “Prostacyclin: a potent antimetastatic agent.” Science 212(4500): 1270-1272.
107. Hoper, M. M., N. F. Voelkel, T. O. Bates, J. D. Allard, M. Horan, D. Shepherd and R. M. Tuder (1997). “Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP.” Am J Respir Cell Mol Biol 17(6): 748-756.
108. Hsieh, Y. C., S. J. Hsieh, Y. S. Chang, C. M. Hsueh and S. L. Hsu (2007). “The lipoxygenase inhibitor, baicalein, modulates cell adhesion and migration by upregulation of integrins and vinculin in rat heart endothelial cells.” Br J Pharmacol 151(8): 1235-1245.
109. Huang, S. P., M. S. Wu, C. T. Shun, H. P. Wang, C. Y. Hsieh, M. L. Kuo and J. T. Lin (2005). “Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma.” J Biomed Sci 12(1): 229-241.
110. Hubbard, W. C., M. C. Alley, G. N. Gray, K. C. Green, T. L. McLemore and M. R. Boyd (1989). “Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors.” Cancer Res 49(4): 826-832.
111. Inagaki, M., T. Tsuri, H. Jyoyama, T. Ono, K. Yamada, M. Kobayashi, Y. Hori, A. Arimura, K. Yasui, K. Ohno, S. Kakudo, K. Koizumi, R. Suzuki, S. Kawai, M. Kato and S. Matsumoto (2000). “Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.” J Med Chem 43(10): 2040-2048.
112. Iniguez, M. A., A. Rodriguez, O. V. Volpert, M. Fresno and J. M. Redondo (2003). “Cyclooxygenase-2: a therapeutic target in angiogenesis.” Trends Mol Med 9(2): 73-78.
113. Inoue, M., H. Itoh, T. Tanaka, T. H. Chun, K. Doi, Y. Fukunaga, N. Sawada, J. Yamshita, K. Masatsugu, T. Saito, S. Sakaguchi, M. Sone, K. Yamahara, T. Yurugi and K. Nakao (2001). “Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma.” Arterioscler Thromb Vasc Biol 21(4): 560-566.
114. Iwamoto, J., Y. Mizokami, K. Takahashi, T. Matsuoka and Y. Matsuzaki (2008). “The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pyloriinduced urokinase-type plasminogen activator system in the gastric cancer cells.” Helicobacter 13(3): 174-182.
115. Jain, R. K. (2003). “Molecular regulation of vessel maturation.” Nat Med 9(6): 685-693.
116. Jain, R. K., K. Schlenger, M. Hockel and F. Yuan (1997). “Quantitative angiogenesis assays: progress and problems.” Nat Med 3(11): 1203-1208.
117. Jakobsen, A., J. P. Mortensen, C. Bisgaard, J. Lindebjerg, S. R. Rafaelsen and V. O. Bendtsen (2008). “A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial.” Int J Colorectal Dis 23(3): 251-255.
118. Jantke, J., M. Ladehoff, F. Kurzel, S. Zapf, E. Kim and A. Giese (2004). “Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis.” Acta Neurochir (Wien) 146(5): 483-494.
119. 2 metabolites play a critical role in pulmonary tumor metastasis in mice.” Anticancer Res 30(9): 3421-3427.
120. Jiang, W. G., A. Douglas-Jones and R. E. Mansel (2003). “Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer.” Prostaglandins Leukot Essent Fatty Acids 69(4): 275-281.
121. Jiang, W. G., A. G. Douglas-Jones and R. E. Mansel (2006). “Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.” Prostaglandins Leukot Essent Fatty Acids 74(2): 125-134.
122. Jiang, W. G., G. Watkins, A. Douglas-Jones and R. E. Mansel (2006). “Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer.” Prostaglandins Leukot Essent Fatty Acids 74(4): 235-245.
123. Jones, D. A., D. P. Carlton, T. M. McIntyre, G. A. Zimmerman and S. M. Prescott (1993). “Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.” J Biol Chem 268(12): 9049-9054.
124. Jones, M. K., H. Wang, B. M. Peskar, E. Levin, R. M. Itani, I. J. Sarfeh and A. S. Tarnawski (1999). “Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.” Nat Med 5(12): 1418-1423.
125. Kang, K. B., T. T. Wang, C. T. Woon, E. S. Cheah, X. L. Moore, C. Zhu and M. C. Wong (2007). “Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.” Int J Radiat Oncol Biol Phys 67(3): 888-896.
126. Kari, G., U. Rodeck and A. P. Dicker (2007). “Zebrafish: an emerging model system for human disease and drug discovery.” Clin Pharmacol Ther 82(1): 70-80.
127. Karlage, K. L., E. Mogalian, A. Jensen and P. B. Myrdal (2010). “Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A/J mouse model.” AAPS PharmSciTech 11(1): 168-173.
128. Kelavkar, U. P., C. Cohen, H. Kamitani, T. E. Eling and K. F. Badr (2000). “Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging.” Carcinogenesis 21(10): 1777-1787.
129. Kenyon, B. M., E. E. Voest, C. C. Chen, E. Flynn, J. Folkman and R. J. D’Amato (1996). “A model of angiogenesis in the mouse cornea.” Invest Ophthalmol Vis Sci 37(8): 1625-1632.
130. Kerbel, R. S., A. Viloria-Petit, G. Klement and J. Rak (2000). "‘Accidental’ antiangiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.” Eur J Cancer 36(10): 1248-1257.
131. Kerjaschki, D., Z. Bago-Horvath, M. Rudas, V. Sexl, C. Schneckenleithner, S. Wolbank, G. Bartel, S. Krieger, R. Kalt, B. Hantusch, T. Keller, K. Nagy-Bojarszky, N. Huttary, I. Raab, K. Lackner, K. Krautgasser, H. Schachner, K. Kaserer, S. Rezar, S. Madlener, C. Vonach, A. Davidovits, H. Nosaka, M. Hammerle, K. Viola, H. Dolznig, M. Schreiber, A. Nader, W. Mikulits, M. Gnant, S. Hirakawa, M. Detmar, K. Alitalo, S. Nijman, F. Offner, T. J. Maier, D. Steinhilber and G. Krupitza (2011). “Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse.” J Clin Invest 121(5): 2000-2012.
132. Khuri, F. R., H. Wu, J. J. Lee, B. L. Kemp, R. Lotan, S. M. Lippman, L. Feng, W. K. Hong and X. C. Xu (2001). “Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.” Clin Cancer Res 7(4): 861-867.
133. Kim, C. E., S. J. Lee, K. W. Seo, H. M. Park, J. W. Yun, J. U. Bae, S. S. Bae and C. D. Kim (2010). “Acrolein increases 5-lipoxygenase expression in murine macrophages through activation of ERK pathway.” Toxicol Appl Pharmacol 245(1): 76-82.
134. Kim, G. Y., J. W. Lee, S. H. Cho, J. M. Seo and J. H. Kim (2009). “Role of the low-affinity leukotriene B4 receptor BLT2 in VEGF-induced angiogenesis.” Arterioscler Thromb Vasc Biol 29(6): 915-920.
135. Kim, H. S., H. R. Youm, J. S. Lee, K. W. Min, J. H. Chung and C. S. Park (2003). “Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer.” Lung Cancer 42(2): 163-170.
136. Kisley, L. R., B. S. Barrett, L. D. Dwyer-Nield, A. K. Bauer, D. C. Thompson and A. M. Malkinson (2002). “Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice.” Carcinogenesis 23(10): 1653-1660.
137. Klampfl, T., E. Bogner, W. Bednar, L. Mager, D. Massudom, I. Kalny, C. Heinzle, W. Berger, S. Stattner, J. Karner, M. Klimpfinger, G. Furstenberger, P. Krieg and B. Marian (2011). “Up-regulation of 12(S)-lipoxygenase induces a migratory phenotype in colorectal cancer cells.” Exp Cell Res 318(6): 768-78.
138. Klurfeld, D. M. and A. W. Bull (1997). “Fatty acids and colon cancer in experimental models.” Am J Clin Nutr 66(6 Suppl): 1530S-1538S.
139. Koeberle, A., H. Northoff and O. Werz (2009). “Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1.” Mol Cancer Ther 8(8): 2348-2355.
140. Kolev, Y., H. Uetake, S. Iida, T. Ishikawa, T. Kawano and K. Sugihara (2007). “Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma.” Ann Surg Oncol 14(10): 2738-2747.
141. Kottke, T., G. Hall, J. Pulido, R. M. Diaz, J. Thompson, H. Chong, P. Selby, M. Coffey, H. Pandha, J. Chester, A. Melcher, K. Harrington and R. Vile (2010). “Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.” J Clin Invest 120(5): 1551-1560.
142. Krieg, P., M. Heidt, M. Siebert, A. Kinzig, F. Marks and G. Furstenberger (2002). “Epidermis-type lipoxygenases.” Adv Exp Med Biol 507: 165-170.
143. Krishnamoorthy, S., R. Jin, Y. Cai, K. R. Maddipati, D. Nie, G. Pages, S. C. Tucker and K. V. Honn (2010). "12-Lipoxygenase and the regulation of hypoxia-inducible factor in prostate cancer cells.” Exp Cell Res 316(10): 1706-1715.
144. Krysan, K., H. Dalwadi, S. Sharma, M. Pold and S. Dubinett (2004). “Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in nonsmall cell lung cancer.” Cancer Res 64(18): 6359-6362.
145. Kuhn, H., M. Walther and R. J. Kuban (2002). “Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications.” Prostaglandins Other Lipid Mediat 68-69: 263-290.
146. Kummer, N. T., T. S. Nowicki, J. P. Azzi, I. Reyes, C. Iacob, S. Xie, I. Swati, N. Suslina, S. Schantz, R. K. Tiwari and J. Geliebter (2012). “Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction.” J Cell Biochem 113(6): 1998-2008.
147. Le Filliatre, G., S. Sayah, V. Latournerie, J. F. Renaud, M. Finet and R. Hanf (2001). “Cyclo-oxygenase and lipoxygenase pathways in mast cell dependent-neurogenic inflammation induced by electrical stimulation of the rat saphenous nerve.” Br J Pharmacol 132(7): 1581-1589.
148. Leahy, K. M., A. T. Koki and J. L. Masferrer (2000). “Role of cyclooxygenases in angiogenesis.” Curr Med Chem 7(11): 1163-1170.
149. Leahy, K. M., R. L. Ornberg, Y. Wang, B. S. Zweifel, A. T. Koki and J. L. Masferrer (2002). “Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.” Cancer Res 62(3): 625-631.
150. Leval, X., F. Julemont, J. Delarge, B. Pirotte and J. M. Dogne (2002). “New trends in dual 5-LOX/COX inhibition.” Curr Med Chem 9(9): 941-962.
151. Li, W., R. J. Xu, Z. Y. Lin, G. C. Zhuo and H. H. Zhang (2009). “Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor.” Med Oncol 26(2): 170-177.
152. Ling, Y., Y. Chen, P. Chen, H. Hui, X. Song, Z. Lu, C. Li, N. Lu and Q. Guo (2011). “Baicalein potently suppresses angiogenesis induced by vascular endothelial growth factor through the p53/Rb signaling pathway leading to G1/S cell cycle arrest.” Exp Biol Med (Maywood) 236(7): 851-858.
153. Liu, J. J., T. S. Huang, W. F. Cheng and F. J. Lu (2003). “Baicalein and baicalin are potent inhibitors of angiogenesis: Inhibition of endothelial cell proliferation, migration and differentiation.” Int J Cancer 106(4): 559-565.
154. Lukiw, W. J., A. Ottlecz, G. Lambrou, M. Grueninger, J. Finley, H. W. Thompson and N. G. Bazan (2003). “Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia.” Invest Ophthalmol Vis Sci 44(10): 4163-4170.
155. Ma, C., Y. Li, J. Ma, Y. Liu, Q. Li, S. Niu, Z. Shen, L. Zhang, Z. Pan and D. Zhu (2011). “Key role of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid in pulmonary vascular remodeling and vascular angiogenesis associated with hypoxic pulmonary hypertension.” Hypertension 58(4): 679-688.
156. Ma, L., P. del Soldato and J. L. Wallace (2002). “Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance.” Proc Natl Acad Sci USA 99(20): 13243-13247.
157. Mariani, T. J., S. Sandefur, J. D. Roby and R. A. Pierce (1998). “Collagenase-3 induction in rat lung fibroblasts requires the combined effects of tumor necrosis factor-alpha and 12-lipoxygenase metabolites: a model of macrophage-induced, fibroblast-driven extracellular matrix remodeling during inflammatory lung injury.” Mol Biol Cell 9(6): 1411-1424.
158. Marques, I. J., F. U. Weiss, D. H. Vlecken, C. Nitsche, J. Bakkers, A. K. Lagendijk, L. I. Partecke, C. D. Heidecke, M. M. Lerch and C. P. Bagowski (2009). “Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model.” BMC Cancer 9: 128.
159. Masferrer, J. L., K. M. Leahy, A. T. Koki, B. S. Zweifel, S. L. Settle, B. M. Woerner, D. A. Edwards, A. G. Flickinger, R. J. Moore and K. Seibert (2000). “Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.” Cancer Res 60(5): 1306-1311.
160. McCabe, N. P., S. H. Selman and J. Jankun (2006). “Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase.” Prostate 66(7): 779-787.
161. McDonough, W., N. Tran, A. Giese, S. A. Norman and M. E. Berens (1998). “Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase.” J Neuropathol Exp Neurol 57(5): 449-455.
162. McLemore, T. L., W. C. Hubbard, C. L. Litterst, M. C. Liu, S. Miller, N. A. McMahon, J. C. Eggleston and M. R. Boyd (1988). “Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients.” Cancer Res 48(11): 3140-3147.
163. Melstrom, L. G., D. J. Bentrem, M. R. Salabat, T. J. Kennedy, X. Z. Ding, M. Strouch, S. M. Rao, R. C. Witt, C. A. Ternent, M. S. Talamonti, R. H. Bell and T. A. Adrian (2008). “Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model.” Clin Cancer Res 14(20): 6525-6530.
164. Merchan, J. R., D. R. Jayaram, J. G. Supko, X. He, G. J. Bubley and V. P. Sukhatme (2005). “Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.” Int J Cancer 113(3): 490-498.
165. Michalik, L., B. Desvergne and W. Wahli (2004). “Peroxisome-proliferator-activated receptors and cancers: complex stories.” Nat Rev Cancer 4(1): 61-70.
166. Miller, K. D., C. J. Sweeney and G. W. Sledge, Jr. (2001). “Redefining the target: chemotherapeutics as antiangiogenics.” J Clin Oncol 19(4): 1195-1206.
167. Moody, T. W., J. Leyton, H. Zakowicz, T. Hida, Y. Kang, S. Jakowlew, L. You, L. Ozbun, H. Zia, J. Youngberg and A. Malkinson (2001). “Indomethacin reduces lung adenoma number in A/J mice.” Anticancer Res 21(3B): 1749-1755.
168. Moon, C., M. Ahn, M. B. Wie, H. M. Kim, C. S. Koh, S. C. Hong, M. D. Kim, N. Tanuma, Y. Matsumoto and T. Shin (2005). “Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes.” Brain Res 1035(2): 206-210.
169. Morteau, O., S. G. Morham, R. Sellon, L. A. Dieleman, R. Langenbach, O. Smithies and R. B. Sartor (2000). “Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.” J Clin Invest 105(4): 469-478.
170. Moussa, O., A. W. Ashton, M. Fraig, E. Garrett-Mayer, M. A. Ghoneim, P. V. Halushka and D. K. Watson (2008). “Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis.” Cancer Res 68(11): 4097-4104.
171. Moussa, O., J. S. Yordy, H. Abol-Enein, D. Sinha, N. K. Bissada, P. V. Halushka, M. A. Ghoneim and D. K. Watson (2005). “Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.” Cancer Res 65(24): 11581-11587.
172. Murata, T., M. I. Lin, K. Aritake, S. Matsumoto, S. Narumiya, H. Ozaki, Y. Urade, M. Hori and W. C. Sessa (2008). “Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo.” Proc Natl Acad Sci USA 105(50): 20009-20014.
173. Murohara, T., J. R. Horowitz, M. Silver, Y. Tsurumi, D. Chen, A. Sullivan and J. M. Isner (1998). “Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin.” Circulation 97(1): 99-107.
174. Murphy, J. F. and D. J. Fitzgerald (2001). “Vascular endothelial growth factor induces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor.” Faseb J 15(9): 1667-1669.
175. Murphy, J. F., F. Lennon, C. Steele, D. Kelleher, D. Fitzgerald and A. C. Long (2005). “Engagement of CD44 modulates cyclooxygenase induction, VEGF generation, and proliferation in human vascular endothelial cells.” Faseb J 19(3): 446-448.
176. Murphy, J. F., C. Steele, O. Belton and D. J. Fitzgerald (2003). “Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3.” Br J Haematol 121(1): 157-164.
177. Mutter, R., B. Lu, D. P. Carbone, I. Csiki, L. Moretti, D. H. Johnson, J. D. Morrow, A. B. Sandler, Y. Shyr, F. Ye and H. Choy (2009). “A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.” Clin Cancer Res 15(6): 2158-2165.
178. Myrdal, P. B., K. Karlage, P. J. Kuehl, B. S. Angersbach, B. A. Merrill and P. D. Wightman (2007). “Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.” Carcinogenesis 28(5): 957-961.
179. Nagatsuka, I., N. Yamada, S. Shimizu, M. Ohira, H. Nishino, S. Seki and K. Hirakawa (2002). “Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer.” Int J Cancer 100(5): 515-519.
180. Narumiya, S. and G. A. FitzGerald (2001). “Genetic and pharmacological analysis of prostanoid receptor function.” J Clin Invest 108(1): 25-30.
181. Nicosia, R. F., R. Tchao and J. Leighton (1982). “Histotypic angiogenesis in vitro: light microscopic, ultrastructural, and radioautographic studies.” In vitro 18(6): 538-549.
182. Nie, D. (2007). “Cyclooxygenases and lipoxygenases in prostate and breast cancers.” Front Biosci 12: 1574-1585.
183. Nie, D., M. Che, A. Zacharek, Y. Qiao, L. Li, X. Li, M. Lamberti, K. Tang, Y. Cai, Y. Guo, D. Grignon and K. V. Honn (2004). “Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility.” Am J Pathol 164(2): 429-439.
184. 2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho.” Cancer Res 68(1): 115-121.
185. Nie, D., S. Krishnamoorthy, R. Jin, K. Tang, Y. Chen, Y. Qiao, A. Zacharek, Y. Guo, J. Milanini, G. Pages and K. V. Honn (2006). “Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells.” J Biol Chem 281(27): 18601-18609.
186. Nie, D., M. Lamberti, A. Zacharek, L. Li, K. Szekeres, K. Tang, Y. Chen and K. V. Honn (2000). “Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.” Biochem Biophys Res Commun 267(1): 245-251.
187. Nie, D., J. Nemeth, Y. Qiao, A. Zacharek, L. Li, K. Hanna, K. Tang, G. G. Hillman, M. L. Cher, D. J. Grignon and K. V. Honn (2003). “Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase.” Clin Exp Metastasis 20(7): 657-663.
188. Nie, D., K. Tang, C. Diglio and K. V. Honn (2000). “Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase.” Blood 95(7): 2304-2311.
189. Nithipatikom, K., M. A. Isbell, W. A. See and W. B. Campbell (2006). “Elevated 12-and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases.” Cancer Lett 233(2): 219-225.
190. Nolte, R. T., G. B. Wisely, S. Westin, J. E. Cobb, M. H. Lambert, R. Kurokawa, M. G. Rosenfeld, T. M. Willson, C. K. Glass and M. V. Milburn (1998). “Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.” Nature 395(6698): 137-143.
191. Norel, X. and C. Brink (2004). “The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues.” Pharmacol Ther 103(1): 81-94.
192. O’Reilly, M. S., L. Holmgren, Y. Shing, C. Chen, R. A. Rosenthal, M. Moses, W. S. Lane, Y. Cao, E. H. Sage and J. Folkman (1994). “Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.” Cell 79(2): 315-328.
193. Ogawa, H., P. Rafiee, P. J. Fisher, N. A. Johnson, M. F. Otterson and D. G. Binion (2003). “Sodium butyrate inhibits angiogenesis of human intestinal microvascular endothelial cells through COX-2 inhibition.” FEBS Lett 554(1-2): 88-94.
194. Ohd, J. F., C. K. Nielsen, J. Campbell, G. Landberg, H. Lofberg and A. Sjolander (2003). “Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas.” Gastroenterology 124(1): 57-70.
195. Okahara, K., B. Sun and J. Kambayashi (1998). “Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells.” Arterioscler Thromb Vasc Biol 18(12): 1922-1926.
196. Pai, R., T. Nakamura, W. S. Moon and A. S. Tarnawski (2003). “Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors.” Faseb J 17(12): 1640-1647.
197. Pai, R., I. L. Szabo, B. A. Soreghan, S. Atay, H. Kawanaka and A. S. Tarnawski (2001). “PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways.” Biochem Biophys Res Commun 286(5): 923-928.
198. Papadimitrakopoulou, V. A., W. N. William, Jr., A. J. Dannenberg, S. M. Lippman, J. J. Lee, F. G. Ondrey, D. E. Peterson, L. Feng, A. Atwell, A. K. El-Naggar, C. O. Nathan, J. I. Helman, B. Du, B. Yueh and J. O. Boyle (2008). “Pilot randomized phase II study of celecoxib in oral premalignant lesions.” Clin Cancer Res 14(7): 2095-2101.
199. Parng, C., W. L. Seng, C. Semino and P. McGrath (2002). “Zebrafish: a preclinical model for drug screening.” Assay Drug Dev Technol 1(1 Pt 1): 41-48.
200. Patricia, M. K., J. A. Kim, C. M. Harper, P. T. Shih, J. A. Berliner, R. Natarajan, J. L. Nadler and C. C. Hedrick (1999). “Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells.” Arterioscler Thromb Vasc Biol 19(11): 2615-2622.
201. Patrignani, P., M. R. Panara, A. Greco, O. Fusco, C. Natoli, S. Iacobelli, F. Cipollone, A. Ganci, C. Creminon, J. Maclouf and et al. (1994). “Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases.” J Pharmacol Exp Ther 271(3): 1705-1712.
202. Pichiule, P., J. C. Chavez and J. C. LaManna (2004). “Hypoxic regulation of angiopoietin-2 expression in endothelial cells.” J Biol Chem 279(13): 12171-12180.
203. Pidgeon, G. P., M. Kandouz, A. Meram and K. V. Honn (2002). “Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells.” Cancer Res 62(9): 2721-2727.
204. Pidgeon, G. P., R. Tamosiuniene, G. Chen, I. Leonard, O. Belton, A. Bradford and D. J. Fitzgerald (2004). “Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2.” Circulation 110(17): 2701-2707.
205. Pola, R., E. Gaetani, A. Flex, T. R. Aprahamian, M. Bosch-Marce, D. W. Losordo, R. C. Smith and P. Pola (2004). “Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors.” J Mol Cell Cardiol 36(3): 363-370.
206. Pold, M., L. X. Zhu, S. Sharma, M. D. Burdick, Y. Lin, P. P. Lee, A. Pold, J. Luo, K. Krysan, M. Dohadwala, J. T. Mao, R. K. Batra, R. M. Strieter and S. M. Dubinett (2004). “Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.” Cancer Res 64(5): 1853-1860.
207. Pradono, P., R. Tazawa, M. Maemondo, M. Tanaka, K. Usui, Y. Saijo, K. Hagiwara and T. Nukiwa (2002). “Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth.” Cancer Res 62(1): 63-66.
208. Prosperi, J. R., S. R. Mallery, K. A. Kigerl, A. A. Erfurt and F. M. Robertson (2004). “Invasive and angiogenic phenotype of MCF-7 human breast tumor cells expressing human cyclooxygenase-2.” Prostaglandins Other Lipid Mediat 73(3-4): 249-264.
209. Pueyo, M. E., Y. Chen, G. D’Angelo and J. B. Michel (1998). “Regulation of vascular endothelial growth factor expression by cAMP in rat aortic smooth muscle cells.” Exp Cell Res 238(2): 354-358.
210. Qualtrough, D., A. Kaidi, S. Chell, H. N. Jabbour, A. C. Williams and C. Paraskeva (2007). “Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells.” Int J Cancer 121(4): 734-740.
211. Raso, E., J. Tovari, K. Toth, S. Paku, M. Trikha, K. V. Honn and J. Timar (2001). “Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKCmediated serine phosphorylation events in melanoma cells.” Thromb Haemost 85(6): 1037-1042.
212. Raut, C. P., S. Nawrocki, L. M. Lashinger, D. W. Davis, S. Khanbolooki, H. Xiong, L. M. Ellis and D. J. McConkey (2004). “Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.” Cancer Biol Ther 3(12): 1217-1224.
213. Reinmuth, N., W. Liu, Y. D. Jung, S. A. Ahmad, R. M. Shaheen, F. Fan, C. D. Bucana, G. McMahon, G. E. Gallick and L. M. Ellis (2001). “Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival.” Faseb J 15(7): 1239-1241.
214. Rhee, J. S., M. Black, U. Schubert, S. Fischer, E. Morgenstern, H. P. Hammes and K. T. Preissner (2004). “The functional role of blood platelet components in angiogenesis.” Thromb Haemost 92(2): 394-402.
215. Ricciotti, E. and G. A. FitzGerald (2011). “Prostaglandins and inflammation.” Arterioscler Thromb Vasc Biol 31(5): 986-1000.
216. Rieck, P. W., S. Cholidis and C. Hartmann (2001). “Intracellular signaling pathway of FGF-2-modulated corneal endothelial cell migration during wound healing in vitro.” Exp Eye Res 73(5): 639-650.
217. Rioux, N. and A. Castonguay (1998). “Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398.” Cancer Res 58(23): 5354-5360.
218. 2 receptor-dependent signaling pathways.” Faseb J 15(9): 1517-1528.
219. Romano, M., A. Catalano, M. Nutini, E. D’Urbano, C. Crescenzi, J. Claria, R. Libner, G. Davi and A. Procopio (2001). "5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor.” Faseb J 15(13): 2326-2336.
220. Rozic, J. G., C. Chakraborty and P. K. Lala (2001). “Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis.” Int J Cancer 93(4): 497-506.
221. 2.” FEBS Lett 580(14): 3368-3374.
222. Salcedo, R., X. Zhang, H. A. Young, N. Michael, K. Wasserman, W. H. Ma, M. Martins-Green, W. J. Murphy and J. J. Oppenheim (2003). “Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells.” Blood 102(6): 1966-1977.
223. Sales, K. J., T. List, S. C. Boddy, A. R. Williams, R. A. Anderson, Z. Naor and H. N. Jabbour (2005). “A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas.” Cancer Res 65(17): 7707-7716.
224. Sandison, J. C. (1924). “A new method for the microscopic study of living growing tissues by the introduction of a transparent chamber in the rabbits ear. " Anat. Rec. 28: 281-287.
225. Schirner, M. and M. R. Schneider (1997). “Inhibition of metastasis by cicaprost in rats with established SMT2A mammary carcinoma growth.” Cancer Detect Prev 21(1): 44-50.
226. Schmedtje, J. F., Jr., Y. S. Ji, W. L. Liu, R. N. DuBois and M. S. Runge (1997). “Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells.” J Biol Chem 272(1): 601-608.
227. Schneider, C. and A. Pozzi (2011). “Cyclooxygenases and lipoxygenases in cancer.” Cancer Metastasis Rev 30(3-4): 277-294.
228. Schneider, M., M. Wortmann, P. K. Mandal, W. Arpornchayanon, K. Jannasch, F. Alves, S. Strieth, M. Conrad and H. Beck (2010). “Absence of glutathione peroxidase 4 affects tumor angiogenesis through increased 12/15-lipoxygenase activity.” Neoplasia 12(3): 254-263.
229. Schwab, J. M., R. Beschorner, R. Meyermann, F. Gozalan and H. J. Schluesener (2002). “Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury.” J Neurosurg 96(5): 892-899.
230. Seed, M. P., J. R. Brown, C. N. Freemantle, J. L. Papworth, P. R. Colville-Nash, D. Willis, K. W. Somerville, S. Asculai and D. A. Willoughby (1997). “The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan.” Cancer Res 57(9): 1625-1629.
231. Segawa, E., S. Hashitani, Y. Toyohara, H. Kishimoto, K. Noguchi, K. Takaoka and M. Urade (2009). “Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line.” Oncol Rep 21(4): 869-874.
232. Seno, H., M. Oshima, T. O. Ishikawa, H. Oshima, K. Takaku, T. Chiba, S. Narumiya and M. M. Taketo (2002). “Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.” Cancer Res 62(2): 506-511.
233. Seo, K. W., S. J. Lee, C. E. Kim, M. R. Yun, H. M. Park, J. W. Yun, S. S. Bae and C. D. Kim (2010). “Participation of 5-lipoxygenase-derived LTB(4) in 4-hydroxynonenalenhanced MMP-2 production in vascular smooth muscle cells.” Atherosclerosis 208(1): 56-61.
234. Shappell, S. B., W. E. Boeglin, S. J. Olson, S. Kasper and A. R. Brash (1999). "15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma.” Am J Pathol 155(1): 235-245.
235. Shemesh, M., M. Gurevich, D. Mizrachi, L. Dombrovski, Y. Stram, M. J. Fields and L. S. Shore (1997). “Expression of functional luteinizing hormone (LH) receptor and its messenger ribonucleic acid in bovine uterine veins: LH induction of cyclooxygenase and augmentation of prostaglandin production in bovine uterine veins.” Endocrinology 138(11): 4844-4851.
236. Shin, V. Y., H. C. Jin, E. K. Ng, J. J. Sung, K. M. Chu and C. H. Cho (2010). “Activation of 5-lipoxygenase is required for nicotine mediated epithelial-mesenchymal transition and tumor cell growth.” Cancer Lett 292(2): 237-245.
237. Shureiqi, I. and S. M. Lippman (2001). “Lipoxygenase modulation to reverse carcinogenesis.” Cancer Res 61(17): 6307-6312.
238. Shureiqi, I., K. J. Wojno, J. A. Poore, R. G. Reddy, M. J. Moussalli, S. A. Spindler, J. K. Greenson, D. Normolle, A. A. Hasan, T. S. Lawrence and D. E. Brenner (1999). “Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers.” Carcinogenesis 20(10): 1985-1995.
239. Shureiqi, I., Y. Wu, D. Chen, X. L. Yang, B. Guan, J. S. Morris, P. Yang, R. A. Newman, R. Broaddus, S. R. Hamilton, P. Lynch, B. Levin, S. M. Fischer and S. M. Lippman (2005). “The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis.” Cancer Res 65(24): 11486-11492.
240. Singh, N. K., V. Kundumani-Sridharan and G. N. Rao (2011). "12/15-Lipoxygenase gene knockout severely impairs ischemia-induced angiogenesis due to lack of Rac1 farnesylation.” Blood 118(20): 5701-5712.
241. Smyth, E. M., T. Grosser, M. Wang, Y. Yu and G. A. FitzGerald (2009). “Prostanoids in health and disease.” J Lipid Res 50 Suppl: S423-428.
242. Solomon, S. D., J. J. McMurray, M. A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W. F. Anderson, A. Zauber, E. Hawk and M. Bertagnolli (2005). “Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.” N Engl J Med 352(11): 1071-1080.
243. Sonoshita, M., K. Takaku, N. Sasaki, Y. Sugimoto, F. Ushikubi, S. Narumiya, M. Oshima and M. M. Taketo (2001). “Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.” Nat Med 7(9): 1048-1051.
244. Stamford, I. F., P. B. Melhuish, M. A. Carroll, C. J. Corrigan, S. Patel and A. Bennett (1986). “Survival of mice with NC carcinoma is unchanged by drugs that are thought to inhibit thromboxane synthesis or increase prostacyclin formation.” Br J Cancer 54(2): 257-263.
245. Stoletov, K., V. Montel, R. D. Lester, S. L. Gonias and R. Klemke (2007). “Highresolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish.” Proc Natl Acad Sci USA 104(44): 17406-17411.
246. Subbarayan, V., X. C. Xu, J. Kim, P. Yang, A. Hoque, A. L. Sabichi, N. Llansa, G. Mendoza, C. J. Logothetis, R. A. Newman, S. M. Lippman and D. G. Menter (2005). “Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.” Neoplasia 7(3): 280-293.
247. Takahashi, H., M. C. Chen, H. Pham, E. Angst, J. C. King, J. Park, E. Y. Brovman, H. Ishiguro, D. M. Harris, H. A. Reber, O. J. Hines, A. S. Gukovskaya, V. L. Go and G. Eibl (2011). “Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells.” Biochim Biophys Acta 1813(8): 1465-1474.
248. Takahashi, Y., F. Kawahara, M. Noguchi, K. Miwa, H. Sato, M. Seiki, H. Inoue, T. Tanabe and T. Yoshimoto (1999). “Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2.” FEBS Lett 460(1): 145-148.
249. Tamura, M., S. Sebastian, B. Gurates, S. Yang, Z. Fang and S. E. Bulun (2002). “Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells.” J Clin Endocrinol Metab 87(7): 3504-3507.
250. Tang, D. G., B. Bhatia, S. Tang and R. Schneider-Broussard (2007). "15-lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size).” Prostaglandins Other Lipid Mediat 82(1-4): 135-146.
251. Tang, D. G., I. M. Grossi, Y. Q. Chen, C. A. Diglio and K. V. Honn (1993). "12(S)-HETE promotes tumor-cell adhesion by increasing surface expression of alpha V beta 3 integrins on endothelial cells.” Int J Cancer 54(1): 102-111.
252. Tang, K., R. L. Finley, Jr., D. Nie and K. V. Honn (2000). “Identification of 12-lipoxygenase interaction with cellular proteins by yeast two-hybrid screening.” Biochemistry 39(12): 3185-3191.
253. Tang, Y., M. T. Wang, Y. Chen, D. Yang, M. Che, K. V. Honn, G. D. Akers, S. R. Johnson and D. Nie (2009). “Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer.” Int J Cancer 124(7): 1545-1551.
254. Tatsuguchi, A., K. Matsui, Y. Shinji, K. Gudis, T. Tsukui, T. Kishida, Y. Fukuda, Y. Sugisaki, A. Tokunaga, T. Tajiri and C. Sakamoto (2004). “Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue.” Hum Pathol 35(4): 488-495.
255. Taylor, P. M., R. J. Woodfield, M. N. Hodgkin, T. R. Pettitt, A. Martin, D. J. Kerr and M. J. Wakelam (2002). “Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway.” Oncogene 21(37): 5765-5772.
256. Teicher, B. A., E. A. Sotomayor and Z. D. Huang (1992). “Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.” Cancer Res 52(23): 6702-6704.
257. Terzuoli, E., S. Donnini, A. Giachetti, M. A. Iniguez, M. Fresno, G. Melillo and M. Ziche (2010). “Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.” Clin Cancer Res 16(16): 4207-4216.
258. Thun, M. J., S. J. Henley and C. Patrono (2002). “Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.” J Natl Cancer Inst 94(4): 252-266.
259. Timar, J., J. Tovari, E. Raso, L. Meszaros, B. Bereczky and K. Lapis (2005). “Plateletmimicry of cancer cells: epiphenomenon with clinical significance.” Oncology 69(3): 185-201.
260. Trapp, V., B. Parmakhtiar, V. Papazian, L. Willmott and J. P. Fruehauf (2010). “Antiangiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture.” Angiogenesis 13(4): 305-315.
261. Tsujii, M., S. Kawano, S. Tsuji, H. Sawaoka, M. Hori and R. N. DuBois (1998). “Cyclooxygenase regulates angiogenesis induced by colon cancer cells.” Cell 93(5): 705-716.
262. Turner, E. C., E. P. Mulvaney, H. M. Reid and B. T. Kinsella (2011). “Interaction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: role in endothelial cell migration and angiogenesis.” Mol Biol Cell 22(15): 2664-2679.
263. van Leyen, K., R. M. Duvoisin, H. Engelhardt and M. Wiedmann (1998). “A function for lipoxygenase in programmed organelle degradation.” Nature 395(6700): 392-395.
264. Varinska, L., L. Mirossay, G. Mojzisova and J. Mojzis (2010). “Antiangogenic effect of selected phytochemicals.” Pharmazie 65(1): 57-63.
265. Viita, H., K. Kinnunen, E. Eriksson, J. Lahteenvuo, M. Babu, G. Kalesnykas, T. Heikura, S. Laidinen, T. Takalo and S. Yla-Herttuala (2009). “Intravitreal adenoviral 15-lipoxygenase-1 gene transfer prevents vascular endothelial growth factor A-induced neovascularization in rabbit eyes.” Hum Gene Ther 20(12): 1679-1686.
266. Viita, H., J. Markkanen, E. Eriksson, M. Nurminen, K. Kinnunen, M. Babu, T. Heikura, S. Turpeinen, S. Laidinen, T. Takalo and S. Yla-Herttuala (2008). "15-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression.” Circ Res 102(2): 177-184.
267. von Rahden, B. H., H. J. Stein, F. Puhringer, I. Koch, R. Langer, G. Piontek, J. R. Siewert, H. Hofler and M. Sarbia (2005). “Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma.” Cancer Res 65(12): 5038-5044.
268. Wang, D. and R. N. DuBois (2007). “Measurement of eicosanoids in cancer tissues.” Methods Enzymol 433: 27-50.
269. Wang, D. and R. N. DuBois (2010). “Eicosanoids and cancer.” Nat Rev Cancer 10(3): 181-193.
270. Wang, D., H. Wang, J. Brown, T. Daikoku, W. Ning, Q. Shi, A. Richmond, R. Strieter, S. K. Dey and R. N. DuBois (2006). “CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer.” J Exp Med 203(4): 941-951.
271. Wang, L., W. Chen, X. Xie, Y. He and X. Bai (2008). “Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.” Exp Oncol 30(1): 42-51.
272. Wang, M. T., K. V. Honn and D. Nie (2007). “Cyclooxygenases, prostanoids, and tumor progression.” Cancer Metastasis Rev 26(3-4): 525-34.
273. Wang, X., G. Li, A. Wang, Z. Zhang, J. R. Merchan and B. Halmos (2011). “Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.” Mol Carcinog Nov 28 [Epub ahead of print].
274. 2R, in human breast cancer.” Int Semin Surg Oncol 2: 23.
275. Wei, J., W. Yan, X. Li, Y. Ding and H. H. Tai (2010). “Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells.” Lung Cancer 69(1): 26-32.
276. Wenger, F. A., M. Kilian, M. Bisevac, C. Khodadayan, M. von Seebach, I. Schimke, H. Guski and J. M. Muller (2002). “Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.” Clin Exp Metastasis 19(8): 681-687.
277. 2 in endothelial cells via p42/p44 mitogen-activated protein kinase.” FEBS Lett 420(1): 28-32.
278. White, R. M., A. Sessa, C. Burke, T. Bowman, J. LeBlanc, C. Ceol, C. Bourque, M. Dovey, W. Goessling, C. E. Burns and L. I. Zon (2008). “Transparent adult zebrafish as a tool for in vivo transplantation analysis.” Cell Stem Cell 2(2): 183-189.
279. Williams, C. S., M. Tsujii, J. Reese, S. K. Dey and R. N. DuBois (2000). “Host cyclooxygenase-2 modulates carcinoma growth.” J Clin Invest 105(11): 1589-1594.
280. Willson, T. M., P. J. Brown, D. D. Sternbach and B. R. Henke (2000). “The PPARs: from orphan receptors to drug discovery.” J Med Chem 43(4): 527-550.
281. Wu, B., J. Li, D. Huang, W. Wang, Y. Chen, Y. Liao, X. Tang, H. Xie and F. Tang (2011). “Baicalein mediates inhibition of migration and invasiveness of skin carcinoma through Ezrin in A431 cells.” BMC Cancer 11: 527.
282. Wu, G., J. Luo, J. S. Rana, R. Laham, F. W. Sellke and J. Li (2006). “Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells.” Cardiovasc Res 69(2): 512-519.
283. Wu, W. K., J. J. Sung, C. W. Lee, J. Yu and C. H. Cho (2010). “Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms.” Cancer Lett 295(1): 7-16.
284. Wu, Y. L., S. L. Fu, Y. P. Zhang, M. M. Qiao and Y. Chen (2005). “Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts.” Biomed Pharmacother 59 Suppl 2: S289-292.
285. Xin, X., S. Yang, J. Kowalski and M. E. Gerritsen (1999). “Peroxisome proliferatoractivated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo.” J Biol Chem 274(13): 9116-9121.
286. Xu, X. M., J. J. Deng, G. J. Yuan, F. Yang, H. T. Guo, M. Xiang, W. Ge and Y. G. Wu (2011). "5-Lipoxygenase contributes to the progression of hepatocellular carcinoma.” Mol Med Report 4(6): 1195-1200.
287. Yang, L., Y. Huang, R. Porta, K. Yanagisawa, A. Gonzalez, E. Segi, D. H. Johnson, S. Narumiya and D. P. Carbone (2006). “Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.” Cancer Res 66(19): 9665-9672.
288. Yang, V. W., J. M. Shields, S. R. Hamilton, E. W. Spannhake, W. C. Hubbard, L. M. Hylind, C. R. Robinson and F. M. Giardiello (1998). “Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis.” Cancer Res 58(8): 1750-1753.
289. Yao, M., W. Zhou, S. Sangha, A. Albert, A. J. Chang, T. C. Liu and M. M. Wolfe (2005). “Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.” Clin Cancer Res 11(4): 1618-1628.
290. Ye, Y. N., W. K. Wu, V. Y. Shin, I. C. Bruce, B. C. Wong and C. H. Cho (2005). “Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.” Carcinogenesis 26(4): 827-834.
291. Ye, Y. N., W. K. Wu, V. Y. Shin and C. H. Cho (2005). “A mechanistic study of colon cancer growth promoted by cigarette smoke extract.” Eur J Pharmacol 519(1-2): 52-57.
292. Yokoyama, I., S. Hayashi, T. Kobayashi, M. Negita, M. Yasutomi, K. Uchida and H. Takagi (1995). “Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor.” Res Exp Med (Berl) 195(4): 209-215.
293. Yokoyama, Y., B. Xin, T. Shigeto and H. Mizunuma (2011). “Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.” J Cancer Res Clin Oncol 137(8): 1219-1228.
294. Yoshida, N., T. Yoshikawa, S. Nakagawa, K. Sakamoto, Y. Nakamura, Y. Naito and M. Kondo (1999). “Effect of shear stress and a stable prostaglandin I2 analogue on adhesive interactions of colon cancer cells and endothelial cells.” Clin Exp Immunol 117(3): 430-434.
295. Yoshida, T., S. Ohki, M. Kanazawa, H. Mizunuma, Y. Kikuchi, H. Satoh, Y. Andoh, A. Tsuchiya and R. Abe (1998). “Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer.” Surg Today 28(7): 740-745.
296. Yoshimoto, A., K. Kasahara, A. Kawashima, M. Fujimura and S. Nakao (2005). “Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.” Oncol Rep 13(6): 1049-1057.
297. Yoshizato, K., S. Zapf, M. Westphal, M. E. Berens and A. Giese (2002). “Thromboxane synthase inhibitors induce apoptosis in migration-arrested glioma cells.” Neurosurgery 50(2): 343-354.
298. Young, M. R. (2004). “Tumor-derived prostaglandin E2 and transforming growth factor-beta stimulate endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN and phosphatidylinositide 3-kinase.” Angiogenesis 7(2): 123-131.
299. Yoysungnoen, P., P. Wirachwong, P. Bhattarakosol, H. Niimi and S. Patumraj (2006). “Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice.” Clin Hemorheol Microcirc 34(1-2): 109-115.
300. Yu, H. B., H. F. Zhang, X. Zhang, D. Y. Li, H. Z. Xue, C. E. Pan and S. H. Zhao (2010). “Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism.” Hepatogastroenterology 57(102-103): 1241-1246.
301. Yu, Z., C. Schneider, W. E. Boeglin, L. J. Marnett and A. R. Brash (2003). “The lipoxygenase gene ALOXE3 implicated in skin differentiation encodes a hydroperoxide isomerase.” Proc Natl Acad Sci USA 100(16): 9162-9167.
302. Zhu, Y. M., N. S. Azahri, D. C. Yu and P. J. Woll (2008). “Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.” BMC Cancer 8: 218.